PRECIGEN, INC. Income (Loss) from Continuing Operations, Per Diluted Share
PRECIGEN, INC. (PGEN) reported Income (Loss) from Continuing Operations, Per Diluted Share of -$0.47 per share for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-19.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare · last filed 2025-03-19
- PRECIGEN, INC. income (loss) from continuing operations, per diluted share for the quarter ending 2023-09-30 was -$0.08.
- PRECIGEN, INC. income (loss) from continuing operations, per diluted share for the quarter ending 2023-06-30 was -$0.08.
- PRECIGEN, INC. income (loss) from continuing operations, per diluted share for the quarter ending 2023-03-31 was -$0.10.
- PRECIGEN, INC. income (loss) from continuing operations, per diluted share for the quarter ending 2022-09-30 was -$0.04.
- PRECIGEN, INC. income (loss) from continuing operations, per diluted share for fiscal 2024 was -$0.47.
- PRECIGEN, INC. income (loss) from continuing operations, per diluted share for fiscal 2023 was -$0.39.
- PRECIGEN, INC. income (loss) from continuing operations, per diluted share for fiscal 2022 was -$0.40.
- PRECIGEN, INC. income (loss) from continuing operations, per diluted share for fiscal 2021 was -$0.56.
| Period end | Income (Loss) from Continuing Operations, Per Diluted Share 3 month | Income (Loss) from Continuing Operations, Per Diluted Share 3 month as first filed | Income (Loss) from Continuing Operations, Per Diluted Share 6 month | Income (Loss) from Continuing Operations, Per Diluted Share 6 month as first filed | Income (Loss) from Continuing Operations, Per Diluted Share 9 month | Income (Loss) from Continuing Operations, Per Diluted Share 9 month as first filed | Income (Loss) from Continuing Operations, Per Diluted Share 12 month | Income (Loss) from Continuing Operations, Per Diluted Share 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | -$0.47 10-K · filed 2025-03-19 | |||||||
| 2023-12-31 | -$0.39 10-K · filed 2025-03-19 | |||||||
| 2023-09-30 | -$0.08 10-Q · filed 2023-11-09 | -$0.26 10-Q · filed 2023-11-09 | ||||||
| 2023-06-30 | -$0.08 10-Q · filed 2023-08-09 | -$0.18 10-Q · filed 2023-08-09 | ||||||
| 2023-03-31 | -$0.10 10-Q · filed 2023-05-10 | |||||||
| 2022-12-31 | -$0.40 10-K · filed 2025-03-19 | |||||||
| 2022-09-30 | -$0.04 10-Q · filed 2023-11-09 | -$0.29 10-Q · filed 2023-11-09 | ||||||
| 2022-06-30 | -$0.13 10-Q · filed 2023-08-09 | -$0.25 10-Q · filed 2023-08-09 | ||||||
| 2022-03-31 | -$0.12 10-Q · filed 2023-05-10 | -$0.10 10-Q · filed 2022-05-09 | ||||||
| 2021-12-31 | -$0.56 10-K · filed 2024-03-19 | -$0.49 10-K · filed 2022-03-01 | ||||||
| 2021-09-30 | -$0.13 10-Q · filed 2022-11-09 | -$0.15 10-Q · filed 2021-11-08 | -$0.43 10-Q · filed 2022-11-09 | -$0.36 10-Q · filed 2021-11-08 | ||||
| 2021-06-30 | -$0.16 10-Q · filed 2022-08-08 | -$0.10 10-Q · filed 2021-08-09 | -$0.29 10-Q · filed 2022-08-08 | -$0.21 10-Q · filed 2021-08-09 | ||||
| 2021-03-31 | -$0.11 10-Q · filed 2022-05-09 | |||||||
| 2020-12-31 | -$0.63 10-K · filed 2023-03-06 | -$0.62 10-K · filed 2022-03-01 | ||||||
| 2020-09-30 | -$0.17 10-Q · filed 2021-11-08 | -$0.39 10-Q · filed 2021-11-08 | ||||||
| 2020-06-30 | -$0.10 10-Q · filed 2021-08-09 | -$0.23 10-Q · filed 2021-08-09 | ||||||
| 2020-03-31 | -$0.13 10-Q · filed 2021-05-10 | |||||||
| 2019-12-31 | -$1.09 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |